B+
Bull case
20%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
AURA
Aura BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
-0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+72.8
Score
AI commentary
The scheduled post-earnings trigger appears unconfirmed: checked company materials show the August 5 filing was a stockholder vote rather than an earnings release, and the IR quarterly-results page still lists Q1 2026 as the latest 2026 result. The August 7 anchor price was $7.99, but no reliable earnings-linked price reaction or analyst revision signal was found. Sentiment therefore remains cautious and monitoring-oriented, with low coverage and limited fresh forward evidence.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventExpanded authorized-share capacityMedium impact
Stockholders approved increasing authorized common shares from 150 million to 500 million. This improves financing flexibility but also creates a potential dilution overhang for a clinical-stage company [#8-K-2026-08-05].
2026-08-08catalystEarnings follow-up lacks a verified company printMedium impact
The scheduled August 6 T3 follow-up could not be reconciled to a confirmed Q2 2026 earnings release. The official IR quarterly-results page still lists Q1 2026 as the latest 2026 result; no verified revenue/EPS surprise, guidance revision, analyst revision, or earnings-linked market reaction is available. The latest confirmed operating update cited CoMpass progress, 2026 clinical milestones, and runway into 2H 2028 [#SEC-8K-2026-05-11] [#PR-EARNINGS-2026-05-12].
2026-11-06event2026 bel-sar clinical data windowsHigh impact
Management's latest confirmed update kept early data from the choroidal-metastases program, ocular-surface proof-of-concept data, and initial NMIBC three-month data on the 2026 calendar. Exact timing and results remain unverified, so this is a monitoring catalyst rather than a high-conviction trade setup [#SEC-8K-2026-05-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology